The increased mucosal mRNA expressions of complement C3 and interleukin-17 in inflammatory bowel disease.
about
The roles and functional mechanisms of interleukin-17 family cytokines in mucosal immunityDo antimicrobial peptides and complement collaborate in the intestinal mucosa?Interleukin 17 contributes to the chronicity of inflammatory diseases such as rheumatoid arthritisImmunopathology of inflammatory bowel diseaseEffect of IL-17 receptor A blockade with brodalumab in inflammatory diseasesThe IL-17 pathway as a major therapeutic target in autoimmune diseasesAtypical Hemolytic Uremic Syndrome and Chronic Ulcerative Colitis Treated with Eculizumab.Atypical hemolytic uremic syndrome in the setting of complement-amplifying conditions: case reports and a review of the evidence for treatment with eculizumab.A genetic variant in the IL-17 promoter is functionally associated with acute graft-versus-host disease after unrelated bone marrow transplantation.Copy number variations and gene polymorphisms of complement components in ocular Behcet's disease and Vogt-Koyanagi-Harada syndrome.Quantitative Analysis of Intestinal Flora of Uygur and Han Ethnic Chinese Patients with Ulcerative Colitis.Role of TH-17 cells in rheumatic and other autoimmune diseasesInflammatory bowel disease: pathogenesis.The Microbiota and Epigenetic Regulation of T Helper 17/Regulatory T Cells: In Search of a Balanced Immune SystemCells, cytokines and inflammatory bowel disease: a clinical perspective.IL-17/IL-17 receptor system in autoimmune disease: mechanisms and therapeutic potential.The role of T helper (TH)17 cells as a double-edged sword in the interplay of infection and autoimmunity with a focus on xenobiotic-induced immunomodulation.The complement system in inflammatory bowel disease.Characteristic immune, apoptosis and inflammatory gene profiles associated with intestinal acute cellular rejection in formalin-fixed paraffin-embedded mucosal biopsies.Update on pathogenesis and predictors of response of therapeutic strategies used in inflammatory bowel diseaseComparative immune responses of corals to stressors associated with offshore reef-based tourist platforms.Gleaning Insights from Fecal Microbiota Transplantation and Probiotic Studies for the Rational Design of Combination Microbial Therapies.Interleukin-17 positive cells accumulate in renal allografts during acute rejection and are independent predictors of worse graft outcome.Regulation of Interleukin-17 Production.High-resolution gene expression profiling using RNA sequencing in patients with inflammatory bowel disease and in mouse models of colitis.High-Fat Diet-Induced Complement Activation Mediates Intestinal Inflammation and Neoplasia, Independent of Obesity.Reciprocal regulation of the survival and apoptosis of Th17 and Th1 cells in the colon.Correlation of genetic risk and messenger RNA expression in a Th17/IL23 pathway analysis in inflammatory bowel disease.The Anti-Inflammatory Effect and Intestinal Barrier Protection of HU210 Differentially Depend on TLR4 Signaling in Dextran Sulfate Sodium-Induced Murine Colitis.IL-17A deficiency mitigates bleomycin-induced complement activation during lung fibrosis.Old and New Lymphocyte Players in Inflammatory Bowel Disease.Mucocutaneous IL-17 immunity in mice and humans: host defense vs. excessive inflammation.Selenium and Selenoproteins in Gut Inflammation-A Review.Berberine Regulates Treg/Th17 Balance to Treat Ulcerative Colitis Through Modulating the Gut Microbiota in the Colon.Aberrantly Expressed Genes and miRNAs in Slow Transit Constipation Based on RNA-Seq Analysis
P2860
Q26750673-3670D220-0387-4E79-97E5-8EEC5FE8EC68Q26865903-D92E5726-7068-488B-9C5C-2D8A68E6F347Q27023777-11E606D3-3121-4120-A45E-E72D2F627FABQ27027636-D75E756D-1D4A-4A33-88D4-152F3A75EE7DQ28076496-52BDED96-08AB-483C-93C3-7B50C7535ED7Q28300826-672E00E0-10A5-46EB-BFA1-FFD9316DFA4AQ33431908-54EC3684-5FBA-488F-B470-345A8459AB9CQ33705135-A99ACC57-394D-4F02-BFB7-F5A485756DFBQ34058468-CE491DFE-784C-41EE-96ED-3CF46EDDB921Q35947745-F9925B6F-6AD0-4470-847B-C01B01010935Q36453678-B6F2CC0B-64FD-4ABA-A266-17A3B92AB769Q36795816-6352E050-A4E0-43C8-92AF-8495C4F51244Q37454586-E6888636-3382-4851-AAE9-9D9C770AE325Q37742909-6E6EFE8E-BEBF-459B-81F4-FC59E1C364FEQ37948155-F11EC888-0647-492E-BBFE-A7F6A856DD93Q37983096-71038A50-FA82-4A0C-979B-4BEED779D113Q38154889-6DBF6E0E-9887-4B65-B957-7E509506770EQ38211992-75445E2F-864F-41DD-AF1C-FB341A10AEEBQ38474327-E30554E3-A04C-4FB5-8AD4-13A1D939A9C8Q38660544-10F22359-B17A-46CB-A4A1-B0700521DCC0Q38780231-AE010D7C-7A2A-47CB-9B49-911DE243EA7CQ38794312-476FF8BB-6D50-49AD-98C8-728AAB7BA8D3Q39729238-E0E37789-960B-4A53-8C92-FC7DF8356A1DQ40508654-A744F92E-C16B-4F5C-A216-CEC5B91A2566Q41185159-1DE2CD2A-525D-409D-9431-DA4A8382CF63Q41653522-53DF42DD-44D4-40FB-AB6E-DC04E22B4C1CQ44043343-7AC6E583-F2B4-46C4-96FD-99B9F5D6AA4FQ45721290-11232FF8-6BF0-4691-A406-EBDEB7F9FC85Q46443053-68E42C91-D363-44C4-A9A4-3186D3FC77BFQ47933314-23B868A3-82D8-442E-B08E-1D847C57728FQ48351328-5473784E-A4CB-4907-8DE4-081C96158954Q49551961-0C574058-56AB-468D-9697-37FF987341B7Q53177593-760015D2-7945-4112-8D57-3BA0157DA66FQ55358872-3C8EC09E-C5C8-48CB-9CBE-19A50F674A2EQ58780488-21C75F98-7708-419D-ACE2-57D871D77AE0
P2860
The increased mucosal mRNA expressions of complement C3 and interleukin-17 in inflammatory bowel disease.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh-hant
name
The increased mucosal mRNA exp ...... in inflammatory bowel disease.
@en
The increased mucosal mRNA exp ...... in inflammatory bowel disease.
@nl
type
label
The increased mucosal mRNA exp ...... in inflammatory bowel disease.
@en
The increased mucosal mRNA exp ...... in inflammatory bowel disease.
@nl
prefLabel
The increased mucosal mRNA exp ...... in inflammatory bowel disease.
@en
The increased mucosal mRNA exp ...... in inflammatory bowel disease.
@nl
P2093
P2860
P1476
The increased mucosal mRNA exp ...... in inflammatory bowel disease.
@en
P2093
K Takeuchi
T Sugihara
T Tsujikawa
Y Fujiyama
P2860
P304
P356
10.1111/J.1365-2249.2010.04093.X
P577
2010-01-19T00:00:00Z